PDS Biotech’s Q2 2024 Update: Clinical Progress
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
- Latest
- Trending
PDS Biotech aligns with FDA for Phase 3 trial, reports Q2 2024 financials with reduced net loss and expenses.
Discover promising biotech stocks with expert insights on market trends and innovative drugmakers worth your investment.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Legend Biotech reports significant revenue growth in Q2 2024, with strategic advancements in CAR-T therapies.
Legend Biotech reports better-than-expected quarterly earnings, $0.49 EPS above estimates, with significant revenue growth.
Natera Inc. sees a 58% revenue surge in Q2 2024, driven by high test volumes and ASP growth, raising guidance ...
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
DCTY's acquisition marks a milestone in China's biotech scene, introducing advanced TCR and CAR T-cell therapies domestically.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Canada allocates 12 million CAD to study oil sands' impact on Indigenous health, addressing pollution concerns.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.